82097-82-3Relevant academic research and scientific papers
Discovery of Pyrazine-Carboxamide-Diphenyl-Ethers as Novel Succinate Dehydrogenase Inhibitors via Fragment Recombination
Li, Hua,Gao, Meng-Qi,Chen, Yan,Wang, Yu-Xia,Zhu, Xiao-Lei,Yang, Guang-Fu
, p. 14001 - 14008 (2020/11/27)
The discovery of novel succinate dehydrogenase inhibitors (SDHIs) has attracted great attention worldwide. Herein, a fragment recombination strategy was proposed to design new SDHIs by understanding the ligand-receptor interaction mechanism of SDHIs. Thre
Pyrazinamide compounds, preparation method and application thereof as well as bactericide
-
Paragraph 0204-0207, (2018/06/04)
The invention relates to the field of pesticide bactericides and discloses pyrazinamide compounds, a preparation method and an application thereof as well as a bactericide. The compounds have the structure shown in formula (I). The pyrazinamide compounds with the novel structure are designed by introducing pyrazine ring fragments in Pyradiflumid and diphenyl ether fragments with wide bioactivity,and the pyrazinamide compounds can be used as novel SDHIs (succinate dehydrogenase inhibitors) or bactericides.
Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT 1A partial agonists
Pettersson, Martin,Campbell, Brian M.,Dounay, Amy B.,Gray, David L.,Xie, Longfei,O'Donnell, Christopher J.,Stratman, Nancy C.,Zoski, Kim,Drummond, Elena,Bora, Gary,Probert, Al,Whisman, Tammy
scheme or table, p. 865 - 868 (2011/02/27)
Compounds with combined norepinephrine reuptake inhibitor (NRI) and serotonin 1A (5-HT1A) partial agonist pharmacology may offer a new therapeutic approach for treating symptoms of neuropsychiatric disorders including ADHD, depression, and anxiety. Herein we describe the design and optimization of novel chemical matter that exhibits favorable dual NRI and 5-HT1A partial agonist activity. Lead compounds in this series were found to be devoid of activity at the dopamine transporter and were shown to be brain penetrant with high receptor occupancy.
RECEPTOR FUNCTION REGULATING AGENT
-
Page/Page column 96, (2010/11/23)
An agent for regulating 14273 receptor function, which is useful as a preventing or treating drug for diabetes mellitus, hyperlipidemia or the like, is provided. An agent for regulating 14273 receptor function comprising a compound containing an aromatic ring and a group capable of releasing a cation.
Tricyclic compounds
-
, (2008/06/13)
A technique is described for the preparation of a wide variety of basic derivatives of linearly condensed tricyclic systems formed by two external benzene nuclei and a 7-membered central ring having 2 chalcogen atoms as hetero atoms. Derivatives of 11H-dibenzo(b,e)-1,4-dioxepin are obtained when the chalcogens are both oxygen atoms; derivatives of 11H-dibenzo(b,f)-1,4-dithiepin are obtained when the chalcogens are both sulfur atoms; derivatives of 6H-dibenz(b,e)-1,4-oxathiepin and 11H-dibenz(b,f)-1,4-oxathiepin are obtained with combinations of sulfur and oxygen atoms as chalcogens.
